1 INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 RESEARCH METHODOLOGY
1.2.1 SECONDARY RESEARCH
1.2.2 DATA ANALYSIS FRAMEWORK
1.2.3 MARKET SIZE ESTIMATION
1.2.4 FORECASTING
1.2.5 PRIMARY RESEARCH AND DATA VALIDATION
2 EUROPE EARLY TOXICITY TESTING MARKET BY TECHNIQUE
2.1 OVERVIEW
2.2 IN VIVO
2.2.1 IN VIVO MARKET, BY COUNTRY
2.3 IN VITRO
2.3.1 IN VITRO MARKET, BY TECHNIQUE
2.3.1.1 CELL CULTURE MARKET, BY COUNTRY
2.3.1.2 PCR MARKET, BY COUNTRY
2.3.1.3 ELISA MARKET, BY COUNTRY
2.3.1.4 WESTERN BLOTTING MARKET, BY COUNTRY
2.3.1.5 PROTEIN BINDING ASSAYS MARKET, BY COUNTRY
2.3.2 IN VITRO MARKET, BY COUNTRY
2.4 IN SILICO
2.4.1 IN SILICO MARKET, BY COUNTRY
3 EUROPE EARLY TOXICITY TESTING MARKET BY TOXICITY ENDPOINT
3.1 OVERVIEW
3.2 GENOTOXICITY
3.2.1 GENOTOXICITY MARKET, BY COUNTRY
3.3 DERMAL TOXICITY
3.3.1 DERMAL TOXICITY MARKET, BY COUNTRY
3.4 SKIN TOXICITY
3.4.1 SKIN TOXICITY MARKET, BY COUNTRY
3.5 OCULAR TOXICITY
3.5.1 OCULAR TOXICITY MARKET, BY COUNTRY
3.6 PHOTOTOXICITY
3.6.1 PHOTOTOXICITY MARKET, BY COUNTRY
3.7 OTHERS
3.7.1 OTHERS MARKET, BY COUNTRY
4 EUROPE EARLY TOXICITY TESTING MARKET BY END USER
4.1 OVERVIEW
4.2 PHARMACEUTICAL INDUSTRY
4.2.1 PHARMACEUTICAL INDUSTRY MARKET, BY COUNTRY
4.3 COSMETIC INDUSTRY
4.3.1 COSMETIC INDUSTRY MARKET, BY COUNTRY
4.4 CHEMICAL INDUSTRY
4.4.1 CHEMICAL INDUSTRY MARKET, BY COUNTRY
4.5 FOOD INDUSTRY
4.5.1 FOOD INDUSTRY MARKET, BY COUNTRY
4.6 OTHERS
4.6.1 OTHERS MARKET, BY COUNTRY
5 EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY
5.1 OVERVIEW
5.2 GERMANY
5.2.1 EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
5.2.2 EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT
5.2.3 EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
5.3 FRANCE
5.3.1 EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
5.3.2 EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT
5.3.3 EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
5.4 ITALY
5.4.1 EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
5.4.2 EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT
5.4.3 EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
5.5 SPAIN
5.5.1 EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
5.5.2 EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT
5.5.3 EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
5.6 UNITED KINGDOM
5.6.1 EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
5.6.2 EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT
5.6.3 EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
5.7 RUSSIA
5.7.1 EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
5.7.2 EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT
5.7.3 EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
5.8 SWEDEN
5.8.1 EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
5.8.2 EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT
5.8.3 EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
5.9 NORWAY
5.9.1 EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
5.9.2 EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT
5.9.3 EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
5.10 DENMARK
5.10.1 EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
5.10.2 EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT
5.10.3 EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
5.11 NETHERLANDS
5.11.1 EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
5.11.2 EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT
5.11.3 EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
5.12 FINLAND
5.12.1 EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
5.12.2 EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT
5.12.3 EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
5.13 REST OF EUROPE
5.13.1 EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
5.13.2 EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT
5.13.3 EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
6 COMPANY PROFILES
6.1 INOTIV INC.
6.1.1 COMPANY OVERVIEW
6.1.2 COMPANY SNAPSHOT
6.1.3 OPERATING BUSINESS SEGMENTS
6.1.4 PRODUCT PORTFOLIO
6.1.5 BUSINESS PERFORMANCE
6.1.6 BUSINESS SEGMENTS
6.1.7 GEOGRAPHIC SEGMENTS
6.1.8 KEY STRATEGIC MOVES AND DEVELOPMENT
6.1.9 PRIMARY MARKET COMPETITORS
6.2 BIO-RAD LABORATORIES INC.
6.2.1 COMPANY OVERVIEW
6.2.2 COMPANY SNAPSHOT
6.2.3 OPERATING BUSINESS SEGMENTS
6.2.4 PRODUCT PORTFOLIO
6.2.5 BUSINESS PERFORMANCE
6.2.6 BUSINESS SEGMENTS
6.2.7 GEOGRAPHIC SEGMENTS
6.2.8 KEY STRATEGIC MOVES AND DEVELOPMENT
6.2.9 PRIMARY MARKET COMPETITORS
6.3 EVOTEC A.G.
6.3.1 COMPANY OVERVIEW
6.3.2 COMPANY SNAPSHOT
6.3.3 OPERATING BUSINESS SEGMENTS
6.3.4 PRODUCT PORTFOLIO
6.3.5 BUSINESS PERFORMANCE
6.3.6 BUSINESS SEGMENTS
6.3.7 GEOGRAPHIC SEGMENTS
6.3.8 KEY STRATEGIC MOVES AND DEVELOPMENT
6.3.9 PRIMARY MARKET COMPETITORS
6.4 AGILENT TECHNOLOGIES INC.
6.4.1 COMPANY OVERVIEW
6.4.2 COMPANY SNAPSHOT
6.4.3 OPERATING BUSINESS SEGMENTS
6.4.4 PRODUCT PORTFOLIO
6.4.5 BUSINESS PERFORMANCE
6.4.6 BUSINESS SEGMENTS
6.4.7 GEOGRAPHIC SEGMENTS
6.4.8 KEY STRATEGIC MOVES AND DEVELOPMENT
6.4.9 PRIMARY MARKET COMPETITORS
6.5 WUXI APPTEC
6.5.1 COMPANY OVERVIEW
6.5.2 COMPANY SNAPSHOT
6.5.3 OPERATING BUSINESS SEGMENTS
6.5.4 PRODUCT PORTFOLIO
6.5.5 BUSINESS PERFORMANCE
6.5.6 BUSINESS SEGMENTS
6.5.7 GEOGRAPHIC SEGMENTS
6.5.8 KEY STRATEGIC MOVES AND DEVELOPMENT
6.5.9 PRIMARY MARKET COMPETITORS
6.6 BRUKER
6.6.1 COMPANY OVERVIEW
6.6.2 COMPANY SNAPSHOT
6.6.3 OPERATING BUSINESS SEGMENTS
6.6.4 PRODUCT PORTFOLIO
6.6.5 BUSINESS PERFORMANCE
6.6.6 BUSINESS SEGMENTS
6.6.7 GEOGRAPHIC SEGMENTS
6.6.8 KEY STRATEGIC MOVES AND DEVELOPMENT
6.6.9 PRIMARY MARKET COMPETITORS
6.7 PERKINELMER INC.
6.7.1 COMPANY OVERVIEW
6.7.2 COMPANY SNAPSHOT
6.7.3 OPERATING BUSINESS SEGMENTS
6.7.4 PRODUCT PORTFOLIO
6.7.5 BUSINESS PERFORMANCE
6.7.6 BUSINESS SEGMENTS
6.7.7 GEOGRAPHIC SEGMENTS
6.7.8 KEY STRATEGIC MOVES AND DEVELOPMENT
6.7.9 PRIMARY MARKET COMPETITORS
6.8 ENZO BIOCHEM INC.
6.8.1 COMPANY OVERVIEW
6.8.2 COMPANY SNAPSHOT
6.8.3 OPERATING BUSINESS SEGMENTS
6.8.4 PRODUCT PORTFOLIO
6.8.5 BUSINESS PERFORMANCE
6.8.6 BUSINESS SEGMENTS
6.8.7 GEOGRAPHIC SEGMENTS
6.8.8 KEY STRATEGIC MOVES AND DEVELOPMENT
6.8.9 PRIMARY MARKET COMPETITORS
6.9 DANAHER CORPORATION
6.9.1 COMPANY OVERVIEW
6.9.2 COMPANY SNAPSHOT
6.9.3 OPERATING BUSINESS SEGMENTS
6.9.4 PRODUCT PORTFOLIO
6.9.5 BUSINESS PERFORMANCE
6.9.6 BUSINESS SEGMENTS
6.9.7 GEOGRAPHIC SEGMENTS
6.9.8 KEY STRATEGIC MOVES AND DEVELOPMENT
6.9.9 PRIMARY MARKET COMPETITORS
6.10 EUROFINS SCIENTIFIC SE
6.10.1 COMPANY OVERVIEW
6.10.2 COMPANY SNAPSHOT
6.10.3 OPERATING BUSINESS SEGMENTS
6.10.4 PRODUCT PORTFOLIO
6.10.5 BUSINESS PERFORMANCE
6.10.6 BUSINESS SEGMENTS
6.10.7 GEOGRAPHIC SEGMENTS
6.10.8 KEY STRATEGIC MOVES AND DEVELOPMENT
6.10.9 PRIMARY MARKET COMPETITORS
6.11 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
6.11.1 COMPANY OVERVIEW
6.11.2 COMPANY SNAPSHOT
6.11.3 OPERATING BUSINESS SEGMENTS
6.11.4 PRODUCT PORTFOLIO
6.11.5 BUSINESS PERFORMANCE
6.11.6 BUSINESS SEGMENTS
6.11.7 GEOGRAPHIC SEGMENTS
6.11.8 KEY STRATEGIC MOVES AND DEVELOPMENT
6.11.9 PRIMARY MARKET COMPETITORS
6.12 LABCORP DRUG DEVELOPMENT.
6.12.1 COMPANY OVERVIEW
6.12.2 COMPANY SNAPSHOT
6.12.3 OPERATING BUSINESS SEGMENTS
6.12.4 PRODUCT PORTFOLIO
6.12.5 BUSINESS PERFORMANCE
6.12.6 BUSINESS SEGMENTS
6.12.7 GEOGRAPHIC SEGMENTS
6.12.8 KEY STRATEGIC MOVES AND DEVELOPMENT
6.12.9 PRIMARY MARKET COMPETITORS
6.13 PROMEGA CORPORATION
6.13.1 COMPANY OVERVIEW
6.13.2 COMPANY SNAPSHOT
6.13.3 OPERATING BUSINESS SEGMENTS
6.13.4 PRODUCT PORTFOLIO
6.13.5 BUSINESS PERFORMANCE
6.13.6 BUSINESS SEGMENTS
6.13.7 GEOGRAPHIC SEGMENTS
6.13.8 KEY STRATEGIC MOVES AND DEVELOPMENT
6.13.9 PRIMARY MARKET COMPETITORS
6.14 INSPHERO AG
6.14.1 COMPANY OVERVIEW
6.14.2 COMPANY SNAPSHOT
6.14.3 OPERATING BUSINESS SEGMENTS
6.14.4 PRODUCT PORTFOLIO
6.14.5 BUSINESS PERFORMANCE
6.14.6 BUSINESS SEGMENTS
6.14.7 GEOGRAPHIC SEGMENTS
6.14.8 KEY STRATEGIC MOVES AND DEVELOPMENT
6.14.9 PRIMARY MARKET COMPETITORS
6.15 THERMO FISHER SCIENTIFIC INC.
6.15.1 COMPANY OVERVIEW
6.15.2 COMPANY SNAPSHOT
6.15.3 OPERATING BUSINESS SEGMENTS
6.15.4 PRODUCT PORTFOLIO
6.15.5 BUSINESS PERFORMANCE
6.15.6 BUSINESS SEGMENTS
6.15.7 GEOGRAPHIC SEGMENTS
6.15.8 KEY STRATEGIC MOVES AND DEVELOPMENT
6.15.9 PRIMARY MARKET COMPETITORS
LIST OF TABLES
TABLE 1. EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 2. EUROPE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 3. EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 4. EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 5. EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD
TABLE 6. UK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 7. UK IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 8. UK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 9. UK EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 10. GERMANY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 11. GERMANY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 12. GERMANY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 13. GERMANY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 14. FRANCE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 15. FRANCE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 16. FRANCE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 17. FRANCE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 18. ITALY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 19. ITALY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 20. ITALY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 21. ITALY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 22. SPAIN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 23. SPAIN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 24. SPAIN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 25. SPAIN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 26. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 27. NETHERLANDS IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 28. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 29. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 30. DENMARK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 31. DENMARK IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 32. DENMARK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 33. DENMARK EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 34. FINLAND EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 35. FINLAND IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 36. FINLAND EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 37. FINLAND EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 38. NORWAY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 39. NORWAY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 40. NORWAY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 41. NORWAY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 42. SWEDEN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 43. SWEDEN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 44. SWEDEN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 45. SWEDEN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 46. RUSSIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 47. RUSSIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 48. RUSSIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 49. RUSSIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 50. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 51. REST OF EUROPE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 52. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 53. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 54. INOTIV INC.: COMPANY SNAPSHOT
TABLE 55. INOTIV INC: OPERATING SEGMENTS
TABLE 56. INOTIV INC.: PR0DUCT PORTFOLIO
TABLE 57. INOTIV INC.: BUSINESS SEGMENT
TABLE 58. INOTIV INC.: GEOGRAPHIC SEGMENT
TABLE 59. INOTIV INC.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 60. BIO-RAD LABORATORIES INC: COMPANY SNAPSHOT
TABLE 61. BIO-RAD LABORATORIES INC: OPERATING SEGMENTS
TABLE 62. BIO-RAD LABORATORIES INC: PRODUCT PORTFOLIO
TABLE 63. BIO-RAD LABORATORIES INC: BUSINESS SEGMENT
TABLE 64. BIO-RAD LABORATORIES INC: GEOGRAPHIC SEGMENT
TABLE 65. BIO-RAD LABORATORIES INC: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 66. EVOTEC A.G.: COMPANY SNAPSHOT
TABLE 67. EVOTEC A.G.: OPERATING SEGMENTS
TABLE 68. EVOTEC A.G.: PRODUCT PORTFOLIO
TABLE 69. EVOTEC A.G.: BUSINESS SEGMENT
TABLE 70. EVOTEC A.G.: GEOGRAPHIC SEGMENT
TABLE 71. EVOTEC A.G.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 72. AGILENT TECHNOLOGIES INC: COMPANY SNAPSHOT
TABLE 73. AGILENT TECHNOLOGIES INC: OPERATING SEGMENTS
TABLE 74. AGILENT TECHNOLOGIES INC: PRODUCT PORTFOLIO
TABLE 75. AGILENT TECHNOLOGIES INC: BUSINESS SEGMENT
TABLE 76. AGILENT TECHNOLOGIES INC: GEOGRAPHIC SEGMENT
TABLE 77. AGILENT TECHNOLOGIES INC: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 78. WUXI APPTEC.: COMPANY SNAPSHOT
TABLE 79. WUXI APPTEC: OPERATING SEGMENTS
TABLE 80. WUXI APPTEC.: PR0DUCT PORTFOLIO
TABLE 81. WUXI APPTEC.: BUSINESS SEGMENT
TABLE 82. WUXI APPTEC.: GEOGRAPHIC SEGMENT
TABLE 83. WUXI APPTEC.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 84. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 85. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 86. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 87. THERMO FISHER SCIENTIFIC: BUSINESS SEGMENT
TABLE 88. THERMO FISHER SCIENTIFIC: GEOGRAPHIC SEGMENT
TABLE 89. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 90. BRUKER: COMPANY SNAPSHOT
TABLE 91. BRUKER: OPERATING SEGMENTS
TABLE 92. BRUKER: PRODUCT PORTFOLIO
TABLE 93. BRUKER: BUSINESS SEGMENT
TABLE 94. BRUKER: GEOGRAPHIC SEGMENT
TABLE 95. BRUKER: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 96. PERKINELMER INC.: COMPANY SNAPSHOT
TABLE 97. PERKINELMER INC.: OPERATING SEGMENTS
TABLE 98. PERKINELMER INC.: PRODUCT PORTFOLIO
TABLE 99. PERKINELMER INC.: BUSINESS SEGMENT
TABLE 100. PERKINELMER INC.: GEOGRAPHIC SEGMENT
TABLE 101. PERKINELMER INC.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 102. ENZO BIOCHEM INC.: COMPANY SNAPSHOT
TABLE 103. ENZO BIOCHEM INC.: OPERATING SEGMENTS
TABLE 104. ENZO BIOCHEM INC.: PRODUCT PORTFOLIO
TABLE 105. ENZO BIOCHEM INC.: BUSINESS SEGMENT
TABLE 106. ENZO BIOCHEM INC.: GEOGRAPHIC SEGMENT
TABLE 107. ENZO BIOCHEM INC.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 108. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 109. DANAHER CORPORATION: OPERATING SEGMENTS
TABLE 110. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 111. DANAHER CORPORATION: BUSINESS SEGMENT
TABLE 112. DANAHER CORPORATION: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 113. EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT
TABLE 114. EUROFINS SCIENTIFIC SE: PRODUCT PORTFOLIO
TABLE 115. EUROFINS SCIENTIFIC SE: GEOGRAPHIC SEGMENT
TABLE 116. EUROFINS SCIENTIFIC SE: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 117. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT
TABLE 118. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: OPERATING SEGMENTS
TABLE 119. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRODUCT PORTFOLIO
TABLE 120. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS SEGMENT
TABLE 121. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: GEOGRAPHIC SEGMENT
TABLE 122. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 123. LABCORP DRUG DEVELOPMENT.: COMPANY SNAPSHOT
TABLE 124. LABCORP DRUG DEVELOPMENT.: OPERATING SEGMENTS
TABLE 125. LABCORP DRUG DEVELOPMENT.: PRODUCT PORTFOLIO
TABLE 126. LABCORP DRUG DEVELOPMENT.: BUSINESS SEGMENT
TABLE 127. LABCORP DRUG DEVELOPMENT.: GEOGRAPHIC SEGMENT
TABLE 128. LABCORP DRUG DEVELOPMENT.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 129. PROMEGA CORPORATION: COMPANY SNAPSHOT
TABLE 130. PROMEGA CORPORATION: PRODUCT PORTFOLIO
TABLE 131. INSPHERO AG: COMPANY SNAPSHOT
TABLE 132. INSPHERO AG: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 1. EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 2. EUROPE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 3. EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 4. EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 5. EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 6. UK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 7. UK IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 8. UK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 9. UK EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 10. GERMANY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 11. GERMANY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 12. GERMANY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 13. GERMANY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 14. FRANCE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 15. FRANCE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 16. FRANCE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 17. FRANCE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 18. ITALY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 19. ITALY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 20. ITALY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 21. ITALY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 22. SPAIN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 23. SPAIN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 24. SPAIN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 25. SPAIN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 26. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 27. NETHERLANDS IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 28. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 29. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 30. DENMARK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 31. DENMARK IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 32. DENMARK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 33. DENMARK EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 34. FINLAND EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 35. FINLAND IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 36. FINLAND EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 37. FINLAND EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 38. NORWAY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 39. NORWAY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 40. NORWAY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 41. NORWAY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 42. SWEDEN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 43. SWEDEN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 44. SWEDEN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 45. SWEDEN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 46. RUSSIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 47. RUSSIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 48. RUSSIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 49. RUSSIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 50. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 51. REST OF EUROPE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 52. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 53. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 54. INOTIV INC.: NET SALES, 2020–2022 ($MILLION)
FIGURE 55. INOTIV INC: PRIMARY MARKET COMPETITORS
FIGURE 56. BIO-RAD LABORATORIES INC CO: NET SALES, 2020–2022 ($MILLION)
FIGURE 57. BIO-RAD LABORATORIES INC: PRIMARY MARKET COMPETITORS
FIGURE 58. EVOTEC A.G.: NET SALES, 2019–2021 ($MILLION)
FIGURE 59. EVOTEC A.G.: PRIMARY MARKET COMPETITORS
FIGURE 60. AGILENT TECHNOLOGIES INC: NET SALES, 2020–2022 ($MILLION)
FIGURE 61. AGILENT TECHNOLOGIES INC: PRIMARY MARKET COMPETITORS
FIGURE 62. WUXI APPTEC.: NET SALES, 2020–2022 ($MILLION)
FIGURE 63. WUXI APPTEC: PRIMARY MARKET COMPETITORS
FIGURE 64. THERMO FISHER SCIENTIFIC: NET SALES, 2019–2021 ($MILLION)
FIGURE 65. THERMO FISHER SCIENTIFIC: PRIMARY MARKET COMPETITORS
FIGURE 66. BRUKER: NET SALES, 2019–2021 ($MILLION)
FIGURE 67. BRUKER: PRIMARY MARKET COMPETITORS
FIGURE 68. PERKINELMER INC.: NET SALES, 2020–2022 ($MILLION)
FIGURE 69. PERKINELMER INC.: PRIMARY MARKET COMPETITORS
FIGURE 70. ENZO BIOCHEM INC.: NET SALES, 2019–2021 ($MILLION)
FIGURE 71. ENZO BIOCHEM INC.: PRIMARY MARKET COMPETITORS
FIGURE 72. DANAHER CORPORATION: NET SALES, 2020–2022 ($MILLION)
FIGURE 73. DANAHER CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 74. EUROFINS SCIENTIFIC SE CO: NET SALES, 2020–2022 ($MILLION)
FIGURE 75. EUROFINS SCIENTIFIC SE: PRIMARY MARKET COMPETITORS
FIGURE 76. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CO: NET SALES, 2020–2022 ($MILLION)
FIGURE 77. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRIMARY MARKET COMPETITORS
FIGURE 78. LABCORP DRUG DEVELOPMENT. CO: NET SALES, 2020–2022 ($MILLION)
FIGURE 79. LABCORP DRUG DEVELOPMENT.: PRIMARY MARKET COMPETITORS
FIGURE 80. PROMEGA CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 81. INSPHERO AG: PRIMARY MARKET COMPETITORS